NDA 015230 · Hikma
Amicar
Aminocaproic Acid · Oral · Antifibrinolytic Agent
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 3, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Jun 4, 1964
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
2 Phase 3, 1 recruiting
FAERS reports
801
606 serious, 144 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2024.
INDICATIONS AND USAGE Aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See Warnings . )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 4, 1964 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- AMICAR · AMINOCAPROIC ACID 0.25GM/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Aminocaproic Acid" as an intervention, any sponsor and status, largest first.
- TXA vs. Amicar in Total Knee and Hip ArthroplastyPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT02030821 · 246 participants · Start Jan 2015 · Primary completion Nov 12, 2017
Drug: Amicar; TXA · For: Blood Loss; Hip Arthritis; Knee Arthritis
Sites: Durham, North Carolina
- Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee ReplacementPivotal-lookingCompleted
Miller Orthopedic SpecialistsAcademic, hospital or other
NCT01873768 · 194 participants · Start Jan 2014 · Primary completion Dec 2015
Drug: Tranexamic Acid (TXA); ε-Aminocaproic Acid (EACA) · For: Osteoarthritis
Sites: Council Bluffs, Iowa
- Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine SurgeryPivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00320619 · 182 participants · Start Sep 2000 · Primary completion Feb 2006
Drug: Epsilon-Aminocaproic Acid (EACA); Placebo · For: Scoliosis; Kyphosis; Lordosis and 2 more
Sites: Baltimore, Maryland
- Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine SurgeryPivotal-lookingCompleted
NYU Langone HealthAcademic, hospital or other
NCT00958581 · 177 participants · Start Dec 2008 · Primary completion Sep 2012
Drug: Tranexamic Acid; Normal Saline and 1 more · For: Scoliosis
Sites: New York, New York
- Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants PatientsPivotal-lookingStatus unknown
Grupo de Estudos Multicentricos em Onco-HematologiaResearch network
NCT02238288 · 154 participants (planned) · Start Dec 2013 · Primary completion Dec 2014
Drug: Aminocaproic acid; lidocaine and epinephrine and 1 more · For: Oral Hemorrhage
Sites: Rio de Janeiro, Brazil
- Bradykinin Receptor Antagonism During Cardiopulmonary BypassPivotal-lookingCompleted
Vanderbilt UniversityAcademic, hospital or other
NCT00223704 · 150 participants · Start May 2006 · Primary completion Jun 2012
Drug: HOE 140; Aminocaproic Acid and 1 more · For: Cardiopulmonary Bypass; Inflammation; Fibrinolysis and 1 more
Sites: Nashville, Tennessee · 2 sites in all
- Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac SurgeryPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT02655653 · 114 participants · Start Oct 2008 · Primary completion Oct 2010
Drug: Epsilon-aminocaproic acid administered; Tranexamic Acid administered · For: Bleeding
- Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac SurgeryPivotal-lookingCompleted
Loma Linda UniversityAcademic, hospital or other
NCT01248104 · 100 participants · Start Mar 2010 · Primary completion Mar 2013
Drug: Tranexamic Acid; Aminocaproic Acid · For: Cardiopulmonary Bypass
Sites: Loma Linda, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemorrhage144
- off label use67
- epistaxis61
- drug ineffective52
- fall40
- death37
- mouth haemorrhage37
- haemarthrosis36
- hypotension30
- contusion29
- pain29
- thrombocytopenia27
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 12 |
| 2007 | 5 |
| 2008 | 9 |
| 2009 | 19 |
| 2010 | 17 |
| 2011 | 34 |
| 2012 | 12 |
| 2013 | 17 |
| 2014 | 18 |
| 2015 | 28 |
| 2016 | 24 |
| 2017 | 16 |
| 2018 | 17 |
| 2019 | 49 |
| 2020 | 45 |
| 2021 | 43 |
| 2022 | 37 |
| 2023 | 78 |
| 2024 | 105 |
| 2025 | 113 |
| 2026 | 98 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis.
Gibbs VN, Champaneria R, Sandercock J, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Antifibrinolytic and Adjunct Hemostatic Agents: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference.
Moynihan KM, Ryerson LM, Le J, et al. · Pediatr Crit Care Med 2024 · Consensus Statement, Systematic Review
- The Effect of Prophylactic Use of Antifibrinolytics During Pediatric Non-Cardiac Surgeries on Bleeding and Transfusions: A Systematic Review and Meta-Analysis.
Hickey KS, Smith M, Karam O, et al. · Paediatr Anaesth 2025 · Systematic Review, Meta-Analysis
- Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?
Zufferey P, Merquiol F, Laporte S, et al. · Anesthesiology 2006 · Meta-Analysis, Review
- Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.
Fremes SE, Wong BI, Lee E, et al. · Ann Thorac Surg 1994 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis.
Kristjansen KA, Djebbara-Bozo N, Nanthan KR, et al. · J Cancer Res Clin Oncol 2025 · Systematic Review, Meta-Analysis
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.